Diabetes portal adds data, more powerful search tools
The AMP Type 2 Diabetes Knowledge Portal (link is external) online library and discovery engine has greatly expanded data and search capabilities to accelerate the pace of scientific advancement. Customizable and simplified navigation, along with aggregated data from more than 100,000 DNA samples from research supported by NIH and other institutions, encourage new understanding of diabetes by increasing users’ ability to share and evaluate content.
A product of NIH’s Accelerating Medicines Partnership (AMP) for type 2 diabetes, the portal — which opened in 2015 — enables user-friendly exploration of international networks of human genetic information linked to type 2 diabetes. At present, researchers and the public can search for information by gene, genetic variant and region; access summaries of genetic variants; and run customized genetic analyses using versatile tools. Individual data will remain confidential.
Anyone can now query detailed data from the portal; previously, only approved researchers could access that content, while others could view aggregate results. A Google account is all that is needed to use the portal, which is also available in Spanish. Because the strength of the portal depends on community participation, people are encouraged to submit data, comments and other materials.
Now including data from European collaborators, administrators continue to expand the network to include more national and international content.
Funding for the portal is provided through NIDDK grants U01DK105554 and U54DK105566 to the Broad Institute of MIT and Harvard, and a Foundation for the National Institutes of Health (FNIH) grant to the University of Michigan to support portal infrastructure and expansion of analytical and visualization tools. Additional support to Broad for the portal is provided by the Carlos Slim Foundation, Mexico City. The awards are part of a larger partnership of academic investigators, NIH and five pharmaceutical companies. AMP T2D was conceived to translate findings on genetic risk factors in type 2 diabetes into valid targets for new therapies or treatments and provide insights into the pathogenesis and heterogeneity of diabetes.
Dr. Camillo Ricordi Delivers Inaugural Lecture Named in His Honor
One of the world’s leading diabetes researchers, Camillo Ricordi, M.D., Director of the University of Miami Miller School of Medicine’s Diabetes Research Institute ( DRI), was chosen to deliver the keynote address at the Cell Transplant Society’s recent international congress …Read More…
The Most Vital Areas in Diabetes Research Today
Do you ever wonder what gets a scientist’s blood pumping? What about diabetes research excites her? What makes her want to work harder to find that cure? Look no further! As a researcher working toward a cure for diabetes, I present you with my top 5 list. Read more.
No More Insulin Shots, Thanks to a New Type of Islet-Cell Transplant
“The cells starting working right away,” says Camillo Ricordi, M.D., director of the DRI and a Stacy Joy Goodman Professor of Surgery…Read More
Exciting Results in Islet Cell Trial
A new transplant technique for insulin-producing islet cells has been trialled on a person with type 1 for the first time and has successfully maintained glucose levels at a healthy level. – Read more
Researchers funded by the National Institutes of Health and the Foundation for the NIH (FNIH) have expanded a recently launched online library, called a knowledge portal, which allows open-access searching of human genetic and clinical information on type 2 diabetes. Individual data will remain confidential. The portal External Web Site Policy includes information from several major international networks, collected from decades of research. Read more…
The Diabetes Research Institute (DRI), a Center of Excellence at the University of Miami Miller School of Medicine, announced today that the first patient in its clinical trial to test for the first time a novel transplant technique for insulin-producing cells was successfully completed. Read more…